Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications

This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Bryce J. B. Nelson [verfasserIn] John Wilson [verfasserIn] Jan D. Andersson [verfasserIn] Frank Wuest [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics

Übergeordnetes Werk:	In: Pharmaceuticals - MDPI AG, 2005, 16(2023), 11, p 1622
Übergeordnetes Werk:	volume:16 ; year:2023 ; number:11, p 1622

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/ph16111622

Katalog-ID:	DOAJ101201524

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ101201524
003	DE-627
005	20240414151746.0
007	cr uuu---uuuuu
008	240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/ph16111622 \|2 doi
035			\|a (DE-627)DOAJ101201524
035			\|a (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RS1-441
100	0		\|a Bryce J. B. Nelson \|e verfasserin \|4 aut
245	1	0	\|a Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT.
650		4	\|a targeted alpha therapy
650		4	\|a alpha particle therapy
650		4	\|a PET imaging
650		4	\|a SPECT imaging
650		4	\|a targeted radionuclide therapy
650		4	\|a theranostics
653		0	\|a Medicine
653		0	\|a R
653		0	\|a Pharmacy and materia medica
700	0		\|a John Wilson \|e verfasserin \|4 aut
700	0		\|a Jan D. Andersson \|e verfasserin \|4 aut
700	0		\|a Frank Wuest \|e verfasserin \|4 aut
773	0	8	\|i In \|t Pharmaceuticals \|d MDPI AG, 2005 \|g 16(2023), 11, p 1622 \|w (DE-627)491437528 \|w (DE-600)2193542-7 \|x 14248247 \|7 nnns
773	1	8	\|g volume:16 \|g year:2023 \|g number:11, p 1622
856	4	0	\|u https://doi.org/10.3390/ph16111622 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/12642c086c284c19a514aa360b6fb03c \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/1424-8247/16/11/1622 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1424-8247 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 16 \|j 2023 \|e 11, p 1622

Indexfelder

author_variant	b j b n bjbn j w jw j d a jda f w fw
matchkey_str	article:14248247:2023----::hrnsiiaigurgtsotreeapahrpporsipoutop
hierarchy_sort_str	2023
callnumber-subject-code	RS
publishDate	2023
allfields	10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622
spelling	10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622
allfields_unstemmed	10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622
allfieldsGer	10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622
allfieldsSound	10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622
language	English
source	In Pharmaceuticals 16(2023), 11, p 1622 volume:16 year:2023 number:11, p 1622
sourceStr	In Pharmaceuticals 16(2023), 11, p 1622 volume:16 year:2023 number:11, p 1622
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica
isfreeaccess_bool	true
container_title	Pharmaceuticals
authorswithroles_txt_mv	Bryce J. B. Nelson @@aut@@ John Wilson @@aut@@ Jan D. Andersson @@aut@@ Frank Wuest @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	491437528
id	DOAJ101201524
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101201524</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414151746.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/ph16111622</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101201524</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ12642c086c284c19a514aa360b6fb03c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Bryce J. B. Nelson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted alpha therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">alpha particle therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PET imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SPECT imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted radionuclide therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">theranostics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John Wilson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan D. Andersson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Frank Wuest</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmaceuticals</subfield><subfield code="d">MDPI AG, 2005</subfield><subfield code="g">16(2023), 11, p 1622</subfield><subfield code="w">(DE-627)491437528</subfield><subfield code="w">(DE-600)2193542-7</subfield><subfield code="x">14248247</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:11, p 1622</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/ph16111622</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/12642c086c284c19a514aa360b6fb03c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1424-8247/16/11/1622</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1424-8247</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2023</subfield><subfield code="e">11, p 1622</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Bryce J. B. Nelson
spellingShingle	Bryce J. B. Nelson misc RS1-441 misc targeted alpha therapy misc alpha particle therapy misc PET imaging misc SPECT imaging misc targeted radionuclide therapy misc theranostics misc Medicine misc R misc Pharmacy and materia medica Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
authorStr	Bryce J. B. Nelson
ppnlink_with_tag_str_mv	@@773@@(DE-627)491437528
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RS1-441
illustrated	Not Illustrated
issn	14248247
topic_title	RS1-441 Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics
topic	misc RS1-441 misc targeted alpha therapy misc alpha particle therapy misc PET imaging misc SPECT imaging misc targeted radionuclide therapy misc theranostics misc Medicine misc R misc Pharmacy and materia medica
topic_unstemmed	misc RS1-441 misc targeted alpha therapy misc alpha particle therapy misc PET imaging misc SPECT imaging misc targeted radionuclide therapy misc theranostics misc Medicine misc R misc Pharmacy and materia medica
topic_browse	misc RS1-441 misc targeted alpha therapy misc alpha particle therapy misc PET imaging misc SPECT imaging misc targeted radionuclide therapy misc theranostics misc Medicine misc R misc Pharmacy and materia medica
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Pharmaceuticals
hierarchy_parent_id	491437528
hierarchy_top_title	Pharmaceuticals
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)491437528 (DE-600)2193542-7
title	Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
ctrlnum	(DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c
title_full	Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
author_sort	Bryce J. B. Nelson
journal	Pharmaceuticals
journalStr	Pharmaceuticals
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
author_browse	Bryce J. B. Nelson John Wilson Jan D. Andersson Frank Wuest
container_volume	16
class	RS1-441
format_se	Elektronische Aufsätze
author-letter	Bryce J. B. Nelson
doi_str_mv	10.3390/ph16111622
author2-role	verfasserin
title_sort	theranostic imaging surrogates for targeted alpha therapy: progress in production, purification, and applications
callnumber	RS1-441
title_auth	Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
abstract	This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT.
abstractGer	This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT.
abstract_unstemmed	This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	11, p 1622
title_short	Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
url	https://doi.org/10.3390/ph16111622 https://doaj.org/article/12642c086c284c19a514aa360b6fb03c https://www.mdpi.com/1424-8247/16/11/1622 https://doaj.org/toc/1424-8247
remote_bool	true
author2	John Wilson Jan D. Andersson Frank Wuest
author2Str	John Wilson Jan D. Andersson Frank Wuest
ppnlink	491437528
callnumber-subject	RS - Pharmacy
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/ph16111622
callnumber-a	RS1-441
up_date	2024-07-03T19:14:42.030Z
_version_	1803586457603932161
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101201524</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414151746.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/ph16111622</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101201524</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ12642c086c284c19a514aa360b6fb03c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Bryce J. B. Nelson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted alpha therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">alpha particle therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PET imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SPECT imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted radionuclide therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">theranostics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John Wilson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan D. Andersson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Frank Wuest</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmaceuticals</subfield><subfield code="d">MDPI AG, 2005</subfield><subfield code="g">16(2023), 11, p 1622</subfield><subfield code="w">(DE-627)491437528</subfield><subfield code="w">(DE-600)2193542-7</subfield><subfield code="x">14248247</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:11, p 1622</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/ph16111622</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/12642c086c284c19a514aa360b6fb03c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1424-8247/16/11/1622</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1424-8247</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2023</subfield><subfield code="e">11, p 1622</subfield></datafield></record></collection>
score	7.399946

Nicht das Richtige dabei?

Schreiben Sie uns!

Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?